CVM - Multiplikator forward rega marang pendapatan CEL-SCI Corporation
The expected P/S valuation demonstrates market expectations for CEL-SCI Corporation (CVM), where reflects the most recent value of the metric. This trend captures the shortage of effective treatment methods for head and neck tumors. Multikine technology creates an advantage by activating immunity prior to surgery to increase survival rates. The innovative platform trains the body to fight the disease, improving overall chances of recovery.
Rincian analitis perusahaan CEL-SCI Corporation
- rega pasar lan target rega analis:
- statistik kapitalisasi pasar:
- rincian valuasi buku bisnis:
- rincian utang lan likuiditas:
Total Utang marang Modal CEL-SCI Corporation|CVM - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas CEL-SCI|CVM - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku CEL-SCI Corporation|CVM - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan CEL-SCI|Likuiditas cepet cel-sci.com
- data bathi bisnis lan rasio investasi:
CVM - Bathi pungkasan|Bathi sing dikarepake CEL-SCI Corporation|CVM - Kapitalisasi marang bathi resik|Rega marang bathi mangsa ngarep CEL-SCI|CVM - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CEL-SCI Corporation|CVM - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) CEL-SCI|CVM - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan cel-sci.com|CVM - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep CEL-SCI Corporation
- indikator volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:CEL-SCI Corp CVM
The implementation of robotic bioreactors into CEL-SCI Corporation (CVM) immunotherapy production directly impacts future revenue streams, as reflected in the forward P/S ratio dynamics. This indicator compares the company's current market value with expected sales volume, allowing investors to determine the premium paid for future growth and assess the fundamental value of assets relative to their projected returns.
Pesaing CEL-SCI Corporation (CVM)
Rasio rega marang prakiraan pendapatan BeiGene ONC|Halozyme Therapeutics, Inc. - Rasio rega marang prakiraan pendapatan|RVMD: Multiplikator forward rega marang pendapatan|Prakiraan rega marang pendapatan Ascentage Pharma Corp (AAPG)|CG Oncology, Inc. (CGON) - Rasio rega marang prakiraan pendapatan|URGN - Rasio kapitalisasi marang dodolan sing dikarepake|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Personalis Inc (PSNL)|Multiplikator Forward P/S ERAS|Rasio kapitalisasi marang dodolan sing dikarepake Delcath Corp|Y-mAbs Therapeutics - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AURA|Candel - Multiplikator Forward P/S|Accuray Inc (ARAY) - Multiplikator forward rega marang pendapatan|sellaslifesciences.com (SLS) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Actuate Therapeutics Inc (ACTU)|Rasio rega marang prakiraan pendapatan Citius Oncology, Inc.|HURA: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Protara Therapeutics, Inc. (TARA)|FATE: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Aadi Bioscience WHWK|TScan Therapeutics Inc (TCRX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CSBR - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan XBIT (XBiotech Inc.)|OSTX: Multiplikator Forward P/S|radiopharmtheranostics.com (RADX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan ARTV|ANL (Adlai Nortye Limited) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S VERU|Rasio kapitalisasi marang dodolan sing dikarepake tempesttx.com|Rasio rega marang prakiraan pendapatan Xilio Therapeutics XLO|Renovaro Biosciences (RENB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|MURA - Rasio rega marang prakiraan pendapatan|KAPA (Kairos Pharma Ltd) - Kapitalisasi marang prakiraan pendapatan|OKUR: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan CytoMed Therapeutics Limited|Multiplikator forward rega marang pendapatan CRIS|Rasio rega marang prakiraan pendapatan APLM|Rasio rega marang prakiraan pendapatan Tharimmune Corp (THAR)|Multiplikator forward rega marang pendapatan advanbiomed.com ADVB|Multiplikator Forward P/S GNPX (Genprex, Inc.)|CLDI - Multiplikator forward rega marang pendapatan|Sunshine Biopharma, Inc. - Multiplikator Forward P/S|XBIO - Multiplikator Forward P/S|Salarius (SLRX) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan PPBT|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan beigene.com (BGNE)|Multiplikator Forward P/S CKPT|ELEV - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan iCAD ICAD|Rega forward marang dodolan IKNA|NTBL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan VIRX (Viracta Therapeutics)|MOR: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NAYA Biosciences Inc|Multiplikator forward rega marang pendapatan AAPGV
